10.3389/fimmu.2021.734229 16 CarvalhoA
The 2021 STEP 4 trial, published in JAMA, showed that people who continued semaglutide after an initial 20-week run-in kept losing weight, while those who switched to placebo regained nearly 7% of their body weight, confirming that ongoing treatment is key to maintaining results
Dimethyl fumarate is currently the only Nrf2 activator with FDA approval for the treatment of multiple sclerosis but is also associated with desensitization and other side effects (Gold et al
An uncommon side effect is inflammation and nodules at the injection site
Nature 349:117127 Dyson MR, Shadbolt SP, Vincent KJ, Perera RL, McCafferty J (2004) Production of soluble mammalian proteins in Escherichia coli: identification of protein features that correlate with successful expression
Eating helps fuel thermogenesis, especially when you're getting enough protein